Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Sarcoma 3 Sarcoma, Synovial 2 Rhabdomyosarcoma 2 Neurofibrosarcoma 2 Liposarcoma 2 Leiomyosarcoma 2 Histiocytoma, Malignant Fibrous 2 Hemangiosarcoma 2 Fibrosarcoma 2 Triple Negative Breast Neoplasms 1 Sarcoma, Alveolar Soft Part 1 Ovarian Neoplasms 1 Neoplasms, Plasma Cell 1 Multiple Myeloma 1 Malignant mesenchymal tumor 1 Liposarcoma, Myxoid 1 Hemangiopericytoma, Malignant 1 Gastrointestinal Stromal Tumors 1 Breast Neoplasms, Male 1 Breast Neoplasms 1

Interventions

Cyclophosphamide 13 fludarabine 7 Trabectedin 4 Radiation Dose Hypofractionation 3 seclidemstat 2 pembrolizumab 2 Topotecan 2 Interferon-gamma 2 selinexor 1 ribociclib 1 pazopanib 1 palbociclib 1 mirdametinib 1 itacitinib 1 interferon gamma-1b 1 fludarabine phosphate 1 cytochrome C synthetase 1 brostallicin 1 baricitinib 1 atezolizumab 1 aldesleukin 1 X-Rays 1 Specimen Handling 1 Sirolimus 1 Radiotherapy 1 Radiation 1 Proton Therapy 1 Pioglitazone 1 Phantoms, Imaging 1 Magnetic Resonance Spectroscopy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Liposarcoma, Myxoid × brostallicin × Clear all

NCT00633165 2010-02-26

SMI-BRS-202

Systems Medicine LLC

Phase 2 Unknown

Sarcoma, Liposarcoma, Myxoid

Data powered by HemOnc (CC BY 4.0) Colophon ⚡